Finally, to assess the in vivo relevance of FN1 in TKI resistance, FN1 expression was quantified in peripheral blood cells from CML patients at diagnosis and during relapse under TKI therapy. This evidence concerns the gene FN1 and chronic myelogenous leukemia, BCR-ABL1 positive.